RNAC Cartesian Therapeutics, Inc.
P/E
--
Forward P/E
25.06
Price/Sales
131.3
Beta
0.721
Div Yield
--
Market Cap
--
Company Analysis
Latest News
Cartesian Therapeutics third quarter 2026 loss narrowed to $0.38 as Phase 3 data nears
Cartesian Therapeutics reported a third quarter 2026 net loss of $11.5 million, significantly narrower than the prior year and outperforming analyst loss...
Cartesian Therapeutics Inc. Q3 2026 Earnings Preview: What Analysts Expect on November 05, 2026
For the third quarter of 2026, analysts expect Cartesian Therapeutics to report consensus revenue of approximately $0.16 million and an EPS loss of $1.02,...